WO2003050091A1 - Deuterierte substituierte pyrazolyl-benzolsulfonamide sowie diese verbindungen enthaltende arzneimittel - Google Patents
Deuterierte substituierte pyrazolyl-benzolsulfonamide sowie diese verbindungen enthaltende arzneimittel Download PDFInfo
- Publication number
- WO2003050091A1 WO2003050091A1 PCT/DE2002/004600 DE0204600W WO03050091A1 WO 2003050091 A1 WO2003050091 A1 WO 2003050091A1 DE 0204600 W DE0204600 W DE 0204600W WO 03050091 A1 WO03050091 A1 WO 03050091A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- deuterated
- methyl
- treatment
- tetradeutero
- independently
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the invention relates to deuterated substituted
- a well-known representative of the substituted pyrazolylbenzenesulfona ide is celecoxib (EP 731795,
- the object of the present invention is to provide substituted pyrazolyl-benzenesulfonamides which have improved pharmacokinetic and / or pharmacodynamic properties compared to the already known compounds.
- the deuterated substituted pyrazolylbenzenesulfonamides according to the invention have significantly better pharmacokinetic and / or pharmacodynamic properties than the undeuterated compounds.
- the object is therefore achieved by providing deuterated substituted pyrazolylbenzenesulfonamides of the general formula I:
- Deuterated substituted pyrazolylbenzenesulfonamides according to the general formula I are preferred, where R 1 is partially or completely deuterated methyl, R 2 is independently H or D and R 3 is independently H or D.
- Deuterated substituted pyrazolyl-benzenesulfonamides according to the general formula I are particularly preferred, where R 1 is methyl or partially or completely deuterated methyl, R 2 is deuterium and R 3 is independently H or D. Particularly preferred are deuterated substituted pyrazolyl-benzenesulfonamides according to the general formula I, where R 1 is methyl or partially or completely deuterated methyl, R 2 is independently H or
- R 3 is deuterium
- Deuterated substituted pyrazolylbenzenesulfonamides according to the general formula I are advantageous, where R 1 is partially or completely deuterated methyl, R 2 is deuterium and R 3 is independently H or D.
- Deuterated substituted pyrazolyl-benzenesulfonamides of the general formula I are particularly advantageous, where R 1 is methyl or partially or completely deuterated methyl and R 2 and R 3 are deuterium.
- Deuterated substituted pyrazolyl-benzenesulfonamides according to the general formula I are particularly advantageous, where R 1 is partially or completely deuterated methyl, R 2 is independently H or D and R 3 is deuterium.
- Deuterated substituted pyrazolyl-benzenesulfonamides according to the general formula I are furthermore advantageous, where R 1 is partially or completely deuterated methyl and R 2 and R 3 are deuterium.
- Methyl acetophenones in the presence of sodium methoxide with ethyl trifluoroacetate see e.g. EP 731795.
- the acid addition salts of the compounds according to the invention can be converted into the free base in a manner known per se, for example using alkalis or ion exchangers.
- the free base can be reacted with inorganic or organic acids, in particular those which form therapeutically usable salts are suitable, win more salts.
- These or other salts of the new compound such as, for example, the picrate, can also be used to purify the free base by converting the free base into a salt, separating it and releasing the base from the salt.
- the present invention also relates to pharmaceuticals for oral, rectal, topical (percutaneous, transdermal, local), subcutaneous, intravenous or intramuscular application, which, in addition to conventional carriers and diluents, contain a compound of the general formula I or its acid addition salt as active ingredient.
- Topical application can take place, for example, in the form of ointments, creams, gels, solutions or by plasters.
- parenteral preparations such as injection solutions are also suitable.
- Suppositories may also be mentioned as preparations.
- Suspending aids such as sodium carboxymethyl cellulose or preservatives such as p-hydroxybenzoates contain.
- Capsules containing active ingredients can be produced, for example, by mixing the active ingredient with an inert carrier such as milk sugar or sorbitol and encapsulating it in gelatin capsules.
- Suitable suppositories can be produced, for example, by mixing them with carriers such as neutral fats or polyethylene glycol or their derivatives.
- Example 1 as a by-product, deuterated
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002471743A CA2471743A1 (en) | 2001-12-12 | 2002-12-11 | Deuterated substituted pyrazolylbenzylsulfonamides and medicaments comprising said compounds |
AU2002357973A AU2002357973A1 (en) | 2001-12-12 | 2002-12-11 | Deuterated substituted pyrazolylbenzylsulfonamides and medicaments comprising said compounds |
HU0402422A HUP0402422A2 (hu) | 2001-12-12 | 2002-12-11 | Deuterizált szubsztituált pirazolil-benzolszulfonamid-származékok, az ezeket tartalmazó gyógyászati készítmények és alkalmazásuk |
JP2003551116A JP2005516009A (ja) | 2001-12-12 | 2002-12-11 | 重水素化された置換ピラゾリル−ベンゼンスルホンアミド並びにこれを含有する医薬品 |
EP02791628A EP1456179A1 (de) | 2001-12-12 | 2002-12-11 | Deuterierte substituierte pyrazolyl-benzolsulfonamide sowie diese verbindungen enthaltende arzneimittel |
US10/498,708 US20050222238A1 (en) | 2001-12-12 | 2002-12-11 | Deuterated substituted pyrazolylbenzylsulfonamides and medicaments comprising said compounds |
IL16243202A IL162432A0 (en) | 2001-12-12 | 2002-12-11 | Deuterated substituted pyrazolylbenzylsulfonamidesand medicaments comprising said compounds |
IS7304A IS7304A (is) | 2001-12-12 | 2004-06-10 | Tvívetnissetin pýrasólýlbensýlsúlfónamíð og lyf sem innihalda téð efnasambönd |
NO20042906A NO20042906L (no) | 2001-12-12 | 2004-07-09 | Deutererte, substituerte pyrazolybenzylsulfonamider og medikamenter som inneholder disse forbindelsene |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10162121.3 | 2001-12-12 | ||
DE10162121A DE10162121A1 (de) | 2001-12-12 | 2001-12-12 | Deuterierte substituierte Pyrazolyl-Benzolsulfonamide sowie diese Verbindungen enthaltende Arzneimittel |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003050091A1 true WO2003050091A1 (de) | 2003-06-19 |
Family
ID=7709640
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DE2002/004600 WO2003050091A1 (de) | 2001-12-12 | 2002-12-11 | Deuterierte substituierte pyrazolyl-benzolsulfonamide sowie diese verbindungen enthaltende arzneimittel |
Country Status (14)
Country | Link |
---|---|
US (1) | US20050222238A1 (de) |
EP (1) | EP1456179A1 (de) |
JP (1) | JP2005516009A (de) |
CN (1) | CN1612863A (de) |
AU (1) | AU2002357973A1 (de) |
CA (1) | CA2471743A1 (de) |
DE (1) | DE10162121A1 (de) |
HU (1) | HUP0402422A2 (de) |
IL (1) | IL162432A0 (de) |
IS (1) | IS7304A (de) |
NO (1) | NO20042906L (de) |
PL (1) | PL370563A1 (de) |
RU (1) | RU2004121033A (de) |
WO (1) | WO2003050091A1 (de) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR054583A1 (es) * | 2005-07-26 | 2007-06-27 | Altana Pharma Ag | Pantoprazol isotopicamente sustituido |
AU2006274036B2 (en) * | 2005-07-26 | 2012-05-24 | Takeda Gmbh | Isotopically substituted proton pump inhibitors |
US7601737B2 (en) * | 2005-07-26 | 2009-10-13 | Nycomed Gmbh | Isotopically substituted proton pump inhibitors |
CA2624179A1 (en) * | 2005-10-06 | 2007-04-12 | Auspex Pharmaceuticals, Inc. | Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties |
US20070287734A1 (en) * | 2006-06-09 | 2007-12-13 | Auspex Pharmaceuticals, Inc. | Preparation and utility of substituted pyrazole compounds with cannabinoid receptor activity |
US20080146573A1 (en) * | 2006-12-04 | 2008-06-19 | Auspex Pharmaceuticals, Inc. | Preparation and utility of substituted oxzolidinones |
WO2008073863A2 (en) * | 2006-12-08 | 2008-06-19 | Auspex Pharmaceuticals, Inc. | Preparation and utility of substituted allylamines |
US20080299216A1 (en) * | 2007-06-01 | 2008-12-04 | Protia, Llc | Deuterium-enriched aripiprazole |
US20090209608A1 (en) * | 2007-08-29 | 2009-08-20 | Protia, Llc | Deuterium-enriched asenapine |
US20090062185A1 (en) * | 2007-08-29 | 2009-03-05 | Protia, Llc | Deuterium-enriched anidulafungin |
US20090062364A1 (en) * | 2007-08-29 | 2009-03-05 | Protia, Llc | Deuterium-enriched celecoxib |
US20090069219A1 (en) * | 2007-09-09 | 2009-03-12 | Protia, Llc | Deuterium-enriched telavancin |
US20090076158A1 (en) * | 2007-09-13 | 2009-03-19 | Protia, Llc | Deuterium-enriched bicalutamide |
US20090075870A1 (en) * | 2007-09-17 | 2009-03-19 | Protia, Llc | Deuterium-enriched caspofungin |
US20090082419A1 (en) * | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched tegaserod |
US20100120756A1 (en) * | 2008-09-17 | 2010-05-13 | Auspex Pharmaceuticals, Inc. | Phenothiazine modulators of h1 receptors |
WO2010056741A2 (en) * | 2008-11-12 | 2010-05-20 | Auspex Pharmaceuticals, Inc. | Phenylacetic acid inhibitors of cyclooxygenase |
AR075584A1 (es) | 2009-02-27 | 2011-04-20 | Intermune Inc | COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO. |
US20120244122A1 (en) * | 2009-05-28 | 2012-09-27 | Masse Craig E | Peptides for the Treatment of HCV Infections |
WO2011038283A1 (en) * | 2009-09-28 | 2011-03-31 | Hoffmann-La Roche Inc. | Novel macrocyclic inhibitors of hepatitis c virus replication |
US20150031768A1 (en) * | 2011-08-19 | 2015-01-29 | The Trustees Of Princeton University | C-halogen bond formation |
KR20230023817A (ko) | 2013-12-03 | 2023-02-17 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 신규한 방법 |
DK3125893T3 (da) * | 2014-04-04 | 2023-11-20 | Intra Cellular Therapies Inc | Deutererede heterocyklus-fusionerede gamma-carboliner som antagonister af 5-ht2a-receptorer |
SI3407889T1 (sl) | 2016-03-25 | 2021-09-30 | Intra-Cellular Therapies, Inc. | Organske spojine in njihova uporaba v zdravljenju ali preprečevanju motenj centralnega živčnega sistema |
US11331316B2 (en) | 2016-10-12 | 2022-05-17 | Intra-Cellular Therapies, Inc. | Amorphous solid dispersions |
RU2767410C2 (ru) | 2017-03-24 | 2022-03-17 | Интра-Селлулар Терапиз, Инк. | Новые композиции и способы |
JP2021536453A (ja) | 2018-08-31 | 2021-12-27 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | 新規方法 |
EP3843739A4 (de) | 2018-08-31 | 2022-06-01 | Intra-Cellular Therapies, Inc. | Neuartige verfahren |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5760068A (en) * | 1993-11-30 | 1998-06-02 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5466823A (en) * | 1993-11-30 | 1995-11-14 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides |
ES2193921T3 (es) * | 1999-12-03 | 2003-11-16 | Pfizer Prod Inc | Compuestos de sulfamoilheteroaril-pirazol como agentes antinflamatorios/analgesicos. |
-
2001
- 2001-12-12 DE DE10162121A patent/DE10162121A1/de not_active Withdrawn
-
2002
- 2002-12-11 AU AU2002357973A patent/AU2002357973A1/en not_active Abandoned
- 2002-12-11 RU RU2004121033/04A patent/RU2004121033A/ru not_active Application Discontinuation
- 2002-12-11 US US10/498,708 patent/US20050222238A1/en not_active Abandoned
- 2002-12-11 HU HU0402422A patent/HUP0402422A2/hu unknown
- 2002-12-11 CN CNA028268423A patent/CN1612863A/zh active Pending
- 2002-12-11 EP EP02791628A patent/EP1456179A1/de not_active Withdrawn
- 2002-12-11 JP JP2003551116A patent/JP2005516009A/ja active Pending
- 2002-12-11 PL PL02370563A patent/PL370563A1/xx not_active Application Discontinuation
- 2002-12-11 IL IL16243202A patent/IL162432A0/xx unknown
- 2002-12-11 CA CA002471743A patent/CA2471743A1/en not_active Abandoned
- 2002-12-11 WO PCT/DE2002/004600 patent/WO2003050091A1/de not_active Application Discontinuation
-
2004
- 2004-06-10 IS IS7304A patent/IS7304A/is unknown
- 2004-07-09 NO NO20042906A patent/NO20042906L/no not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5760068A (en) * | 1993-11-30 | 1998-06-02 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation |
Also Published As
Publication number | Publication date |
---|---|
IS7304A (is) | 2004-06-10 |
IL162432A0 (en) | 2005-11-20 |
HUP0402422A2 (hu) | 2005-03-29 |
PL370563A1 (en) | 2005-05-30 |
US20050222238A1 (en) | 2005-10-06 |
CN1612863A (zh) | 2005-05-04 |
CA2471743A1 (en) | 2003-06-19 |
NO20042906L (no) | 2004-07-09 |
JP2005516009A (ja) | 2005-06-02 |
DE10162121A1 (de) | 2003-06-18 |
AU2002357973A1 (en) | 2003-06-23 |
RU2004121033A (ru) | 2006-01-10 |
EP1456179A1 (de) | 2004-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003050091A1 (de) | Deuterierte substituierte pyrazolyl-benzolsulfonamide sowie diese verbindungen enthaltende arzneimittel | |
EP1456192A1 (de) | Deuterierte substituierte dihydrofuranone sowie diese verbindungen enthaltende arzneimittel | |
DE2623129B2 (de) | U-Diphenyl-3-<imidazol-l-yl) -propan-2-ole, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel | |
DE10123129A1 (de) | Deuterierte 3-Piperidinopropiophenone sowie diese Verbindungen enthaltende Arzneimittel | |
WO2002102743A2 (de) | Deuterierte n- und alpha-substituierte diphenylalkoyxessigsäureaminoalkylester sowie diese verbindungen enthaltende arzneimittel | |
DE1545670A1 (de) | Neue Diazacycloalkane | |
EP0056866B1 (de) | Phenylpiperazinderivate von Hetarylphenolen und Hetarylanilinen, ihre Herstellung und diese enthaltende therapeutische Mittel | |
EP0034276B1 (de) | Phenylpiperazinderivate von 1,3,4-Oxadiazolylphenolen, ihre Herstellung und diese enthaltende therapeutische Mittel | |
WO2003039439A2 (de) | Deuterierte pyrazolopyrimidinone sowie diese verbindungen enthaltende arzneimittel | |
DE2658762A1 (de) | Neue o-alkylierte oxime, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel | |
DE4119756A1 (de) | Aminoalkylsubstituierte 5-mercaptothiazole, ihre herstellung und verwendung | |
DE3343671A1 (de) | Aminopropanolderivate von substituierten 2-hydroxy-propiophenonen, verfahren zu ihrer herstellung und diese enthaltende therapeutische mittel | |
EP0073931B1 (de) | Neue Anilino-1,2,3-triazol-Derivate, diese enthaltende Arzneimittel sowie Verfahren zu deren Herstellung und deren Verwendung | |
DE10214228A1 (de) | Deuterierte substitutierte Indole sowie diese Verbindungen enthaltende Arzneimittel | |
EP0004918B1 (de) | Optisch aktives (-)-2-(2,4-Dichlorphenoxy)-1-(imidazol-1-yl)-4,4-dimethyl-pentan-3-on Verfahren zu seiner Herstellung sowie Arzneimittel, die diese Verbindung enthalten | |
DE2943406A1 (de) | Aminoderivate des 2-methyl-5-(2-hydroxystyryl)-1,3,4-thiadiazols | |
DE4000213A1 (de) | O-hydroxy-ss-(1-naphthyl)-propiophenonderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel | |
EP0202461A1 (de) | Substituierte 2-(N-Alkinyl-N-phenylamino)imidazolinderivate, deren Säureadditionssalze, diese enthaltende Arzneimittel und Verfahren zu deren Herstellung | |
DE4112353A1 (de) | 1,3,4-trisubstituierte piperidin-derivate, ihre herstellung und verwendung | |
EP0164010A2 (de) | 3-Nitro-dihydropyridine, Verfahren zu ihrer Herstellung sowie ihre Verwendung in Arzneimitteln | |
DE4235603A1 (de) | Arylalkoxythiocumarine, Verfahren zu ihrer Herstellung und diese enthaltende therapeutische Mittel | |
DE4119755A1 (de) | Aminoalkylsubstituierte 2-amino-1,3,4-thiadiazole, ihre herstellung und verwendung | |
DE10205432A1 (de) | Deuterierte biphenylsubstituierte Spirocyclopentanimidazoline sowie diese Verbindungen enthaltende Arzneimittel | |
EP0296265A1 (de) | Aminopropanolderivate von 3-(3-Hydroxyphenyl)-1-propanon-derivaten, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel | |
EP0006971A1 (de) | Aminoderivate des 2-Methyl-5-(2-hydroxystyryl)-1,3,4-thiadiazols, Verfahren zu ihrer Herstellung und diese enthaltende therapeutische Mittel |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003551116 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 162432 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2471743 Country of ref document: CA Ref document number: 360/MUMNP/2004 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20028268423 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 533991 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002791628 Country of ref document: EP Ref document number: 2002357973 Country of ref document: AU Ref document number: 2004121033 Country of ref document: RU |
|
WWP | Wipo information: published in national office |
Ref document number: 2002791628 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10498708 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2002791628 Country of ref document: EP |